Merging clinical research and standard healthcare – Nordic Precision Cancer Medicine Symposium 2025

Bjerrum A, Fanø A, Lassen U. Realizing precision oncology through shared real-world data infrastructure. Acta Oncol. 2026;65:156–58.

https://doi.org/10.2340/1651-226X.2026.45074 DOI: https://doi.org/10.2340/1651-226X.2026.45074

Welén K, Ahlberg M, Akre O, Aly M, Andersson J, Andersson P, et al. SPRINTR: Swedish PRecision medicine Initiative for Novel Treatments and Research – towards efficient recruitment to clinical trials for prostate cancer. Acta Oncol. 2026;65.

Acanda De La Rocha AM, Berlow NE, Fader M, Coats ER, Saghira C, Espinal PS, et al. Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers. Nat Med. 2024;30:990–1000.

https://doi.org/10.1038/s41591-024-02848-4 DOI: https://doi.org/10.1038/s41591-024-02848-4

Martling A, Myrberg IH, Nilbert M, Grönberg H, Granath F, Eklund M, et al. Low-dose aspirin for PI3K-altered localized colorectal cancer. N Eng J Med. 2025;393:1051–64.

https://doi.org/10.1056/NEJMoa2504650 DOI: https://doi.org/10.1056/NEJMoa2504650

Holm MB, Busund S, Rihel R, Sahakyan MA, Gladhaug IP, Verbeke CS, et al. Outcome of resectable distal cholangiocarcinoma in a European patient cohort: comparison of the 7th and 8th edition of the UICC/AJCC TNM classification. Acta Oncol. 2026;65:148–55.

https://doi.org/10.2340/1651-226X.2026.44965 DOI: https://doi.org/10.2340/1651-226X.2026.44965

Taskén K, Haj Mohammad SF, Fagereng GL, Falk RS, Helland Å, van Waalwijk van Doorn-Khosrovani SB, et al. PCM4EU and PRIME-ROSE: collaboration for implementation of precision cancer medicine in Europe. Acta Oncol. 2024;63:385–91.

https://doi.org/10.2340/1651-226X.2024.34791 DOI: https://doi.org/10.2340/1651-226X.2024.34791

van der Pol H, Kringelbach T, Agudo MM, Stav GB, Fagereng GL, Fiocco M, et al. Procedures of data merging in precision cancer medicine: the PRIME-ROSE Project. Acta Oncol. 2026;65:1–8.

https://doi.org/10.2340/1651-226X.2026.44889 DOI: https://doi.org/10.2340/1651-226X.2026.44889

Agudo MM, van der Pol H, Stav GB, Kringelback T, Puco K, Flobak Å, et al. ‘Crossing borders’ in data standardisation: application of OMOP CDM in an international clinical trial network in precision cancer medicine. Acta Oncol. 2026;65:159–63. DOI: https://doi.org/10.2340/1651-226X.2026.45120

https://doi

Slørdahl KS, Puco K, Falk RS, Dyvik I, Brabrand S, Niehusmann P, et al. Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial. Acta Oncol. 2026;65:90–6.

https://doi.org/10.2340/1651-226X.2026.45086 DOI: https://doi.org/10.2340/1651-226X.2026.45086

Abel E, Östling P, Hult EH, Kulbacka K, Babacic H, Baan A, et al. The FOCU.SE Trial: a nationwide swedish drug repurposing protocol and research framework. Acta Oncol. 2026.

Haraldsdottir S., Hilmarsdottir B, Barkardottir RB, Birgisson H, Gunnarsson Ö, Guðbjartsson T, et al. Targeted therapy in the treatment of lung cancer in Iceland 2010–2023. Acta Oncol. 2026.

Sommervoll FÅ, Horndalsveen H, Sommervoll DE, Koivunen J, Halvorsen TO, Grønberg BH, et al. How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab. Acta Oncol. 2026.

Zeverijn LJ, van Waalwijk van Doorn-Khosrovani SB, Pisters van Roy AAMG, Timmers L, Tran THL, de Boer JE, et al. Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform. Lancet Oncol. 2022;23:198–201.

https://doi.org/10.1016/S1470-2045(21)00707-5 DOI: https://doi.org/10.1016/S1470-2045(21)00707-5

Leopold C, Huisman AH, Vlaar KJGM, Bloemendal HJ, van Waalwijk van Doorn-Khosrovani SB. Stakeholders’ experiences with a clinician-imitated access program linking evidence generation and reimbursement for precision cancer treatments: the Drug Access Protocol in the Netherlands. Acta Oncol. 2026;65:22–31.

https://doi.org/10.2340/1651-226X.2026.45000 DOI: https://doi.org/10.2340/1651-226X.2026.45000

Frisell O, Aas E, Henkel PS, Fagereng GL, Taskén K, Hult EH, et al. A conceptual health economic modelling framework to assess the cost-effectiveness of molecular target-driven treatment regimens in oncology. Acta Oncol. 2026;65:141–7.

https://doi.org/10.2340/1651-226X.2026.45088 DOI: https://doi.org/10.2340/1651-226X.2026.45088